ClinicalTrials.gg
Active, not recruitingNCT04127578Updated Oct 13, 2026

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

A Phase 1/2 interventional study of LY3884961 and Methylprednisolone in Parkinson Disease, sponsored by Prevail Therapeutics. Active, not recruiting at 15 sites in 2 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Parkinson Disease by Eli Lilly and Company — 2 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Eli Lilly and Company.

Planned enrollment
7th of 10
32 · median 85
Started
2020
the only one that year
Phase 1/2
2 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Parkinson Disease by Eli Lilly and Company, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

2 of the 11 studies in Parkinson Disease by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Parkinson Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinson's Disease
  • GBA1 mutation
  • Glucocerebrosidase
  • PD-GBA
  • Parkinson's Disease Gene Therapy
  • AAV9
  • Gene Therapy
  • GBA
  • Gaucher Disease
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lbs) and a (BMI) of 18 to 34 kg/m2.
  • Diagnosis of Parkinson's Disease (PD) per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
  • Hoehn and Yahr Stage III-IV (as determined in Practically Defined OFF state).
  • Stable use of background medications at least 8 weeks prior to product (IP) administration, including but not limited to those used for treatment of PD. Gaucher Disease-PD patients receiving GD treatments should be on a stable regimen of their ERT or substrate replacement therapy (SRT) medication for at least 3 months prior to screening.
  • At least 1 pathogenic GBA1 mutation confirmed by the central laboratory
  • Negative screening test for Mycobacterium tuberculosis (MTB), documented negative MTB test within 1 year prior to Screening, or clearance by an infectious disease specialist.
  • Patient and/or patient's legally authorized representative (LAR) has the ability to understand the purpose and risks of the study and provide written and authorization to use protected health information in accordance with national and local privacy regulations.
  • Patient has a reliable study partner/informant (e.g., family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales). The study partner should have regular contact with the patient (in person or via phone/video communication). The study partner must sign a separate partner informed consent form (ICF) indicating that she/he understands the study requirements and is willing to participate and attend study visits requiring study partner input.
  • Women of nonchildbearing potential must be either surgically sterile or . Men and women of must use a highly effective method of consistently and correctly for the duration of the study including the long-term follow-up. Individuals in an exclusively same sex relationship (as their preferred and usual lifestyle) are not required to use contraception.
  • Men must agree to abstain from sperm donation for the duration of the study, including long-term follow-up.
  • Women must agree to abstain from egg donation for the duration of the study, including long-term follow-up.
  • Women of childbearing potential cannot be pregnant or lactating/breastfeeding and must have a negative result for serum pregnancy test at Screening.
  • Patient is generally ambulatory, not dependent on walker or wheelchair
  • Patient is living in the community (i.e., not in nursing home); some levels of assisted living may be permitted at the discretion of the Investigator.
  • Pneumococcal and shingles vaccines are required within 10 years of Screening (allowed to be performed during Screening but must be given at least 4 weeks prior to start of the treatment).
  • Patient is up to date with age and gender-appropriate cancer screening as per local standard of care based on Principal Investigator's (PI) judgment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a significant CNS disease other than Parkinson's Disease (PD) that may be a cause for the patient's PD symptoms or may confound study objectives.
  • (Montreal Cognitive Assessment) score of \<14
  • Spinal, cervical, or brain MRI/magnetic resonance angiography (MRA) indicating abnormality, including evidence of prior hemorrhage, infarct >1 cm3 or >3 lacunar infarcts, or a structural abnormality deemed a to intracisternal injection.
  • or contraindications to and/or, sirolimus use (including but not limited to osteoporosis with vertebral fractures within 1 year prior to Screening, uncontrolled hypertension, poorly controlled diabetes, uncontrolled hyperlipidemia or hypercholesterolemia as per Investigator assessment.
  • Concomitant disease or condition within 6 months of Screening that could interfere with, or treatment of which might interfere with, the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable safety risk to the patient or interfere with the patient's ability to comply with study procedures; including, but not limited to the following:

    1. Evidence of clinically significant liver pathology;
    2. Unstable disease; autoimmune disease requiring chronic ;
    3. Poorly controlled/not adequately managed diabetes (Screening glycosylated [] ≥ 7%);
    4. History of unstable angina, myocardial infarction, chronic heart failure ( Class III or IV), or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to Screening;
    5. Clinically significant 12-lead (ECG) abnormalities at Screening, as determined by the Investigator;
    6. Uncontrolled hypertension;
    7. History of cancer, including B-cell cancers, within 5 years of Screening with the exception of fully excised non-melanoma skin cancers, non- prostate cancer, and full treated ductal carcinoma in situ, provided it has been stable for at least 6 months;
    8. History or current alcohol or drug abuse within 2 years of Screening;
    9. Any current psychiatric diagnosis that may interfere with patient's ability to perform study procedures and all assessments;
    10. At imminent risk of self-harm;
    11. Any medical disorders that, in the opinion of the Investigator, could interfere with study-related procedures (including safe performance of lumbar puncture [LP] or intracisternal injection), such as prohibitive spinal diseases, bleeding diathesis, clinically significant coagulopathy,, thrombocytopenia, or increased intracranial pressure;
    12. Documented stroke or within 1 year prior to Screening;
    13. History of seizure or unexplained blackouts within 10 years prior to Screening;
    14. Currently active infection or a severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g. meningitis, encephalitis]) within 12 weeks prior to Screening;
    15. History of severe allergic or anaphylactic reactions. History of hypersensitivity to any inactive ingredient of the IP or protocol-required immunosuppressant medications.
    16. Acute or chronic: (HBV); (HCV) infection must have completed curative antiviral treatment with HCV viral load below the limit of quantification or be HCV RNA negative due to prior treatment or natural resolution to be eligible for enrollment.
  • Clinically significant abnormalities in laboratory test results at Screening.
  • Participation within 3 months prior to Screening in another therapeutic drug or device study with purported disease-modifying effects on PD, unless it can be documented that the patient received placebo.
  • History of deep brain stimulator placement, focused ultrasound, or surgery for PD
  • Any type of prior gene or cell therapy.
  • Immunizations () in the 4 weeks prior to Screening. Note: Pneumococcal and shingles vaccine administrations are allowed during the Screening period (patients not previously vaccinated should receive pneumococcal and/or shingles vaccine administration at least 4 weeks prior to initiation of Immunosuppression regimen).
  • Use of ambroxol within 8 weeks of dosing.
  • Use of blood thinners in the 2 weeks prior to Screening lumbar puncture (LP) or intra-cisterna magna (ICM) procedure, or the anticipated need to initiate blood thinners during the study. Antiplatelet therapies (e.g., prophylactic aspirin, clopidogrel) are acceptable if the patient is medically able to temporarily stop 48 hours to 7 days (depending on the antiplatelet medication used) prior to and at least 48 hours after intracisternal injection and lumbar puncture.
  • Contraindications or intolerance to imaging methods (MRI, MRA, CT, DaT-SPECT) inducing claustrophobia and/or intolerance to contrast agents used for MRI, MRA or CT.
  • Contraindications to general anesthesia or deep sedation.
  • Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription, at Screening and Day -1. Note: Use of medical marijuana is permitted provided the patient is on a stable regimen. It is also permitted if the patient resides in a state in which the recreational use of marijuana is legalized, so long as the patient does not meet drug abuse criteria (as defined in the Fifth Edition).
  • Patient is generally frail or has any medical condition, for which, in view of the Investigator, participation in the study would not be in the best interest of the patient or is likely to prohibit further participation during the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Biological: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus

  • Experimental
    Dose Level 2

    Biological: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus

Interventions

  • BiologicalLY3884961

    Participants will receive a single dose of LY3884961, administered intra-cisterna magna

  • 6 IV pulses administered as concomitant medication over 3 months

  • Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

06

What researchers measure

Primary outcomes

  1. Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: 5 years

  2. Incidence of procedure or treatment-emergent AEs measured by brain MRI, spine MRI and nerve conduction study (NCS)

    Time frame: 5 years

  3. Treatment emergent immunogenicity of AAV9 in blood

    Time frame: Thru month 24

  4. Change from baseline in immunogenicity of AAV9 in blood

    Time frame: Baseline and Month 24

  5. Treatment emergent immunogenicity of GCase in blood

    GCase (glucocerebrosidase)

    Time frame: Thru Month 24

  6. Change from baseline in immunogenicity of GCase in blood

    GCase (glucocerebrosidase)

    Time frame: Baseline and Months 24

  7. Treatment emergent immunogenicity of Nfl in blood

    GCase (glucocerebrosidase)

    Time frame: Thru Month 24

  8. Change from baseline in immunogenicity of Nfl in blood

    GCase (glucocerebrosidase)

    Time frame: Baseline and Month 24

  9. Treatment emergent immunogenicity of AAV9 in CSF

    Time frame: Thru Month 24

  10. Change in immunogenicity of AAV9 in CSF

    Time frame: Baseline and Month 12

  11. Treatment emergent immunogenicity of GCase in CSF

    Time frame: Thru Month 24

  12. Change in immunogenicity of GCase in CSF

    Time frame: Baseline, and Months 12

Secondary outcomes

  1. Change in glycolipid levels in blood

    Time frame: Baseline, Days 7, 14, and 21, and Months 1, 1.5, 2, 3, 6, 9 and 12

  2. Change in GCase levels

    Time frame: Baseline, Days 7, 14, and 21, and Months 1, 1.5, 2, 3, 6, 9 and 12

  3. GCase enzyme activity levels in blood

    Time frame: Days 7, 14, and 21, and Months 1, 1.5, 2, 3, 6, 9 and 12

  4. Change in glycolipid levels in CSF

    Time frame: Baseline, and Months 2, 6, and 12

  5. Change in GCase levels in CSF

    Time frame: Baseline, and Months 2, 6, and 12

  6. GCase enzyme activity levels in CSF

    Time frame: Months 2, 6, and 12

07

Study locations

15 sites
  • Mayo Clinic, 13400 E. Shea Boulevard
    Scottsdale, Arizona 85259, United States
  • Esperanza Clinical, 25220 Hancock Avenue
    Murrieta, California 92562, United States
  • Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510
    Englewood, Colorado 80113-2776, United States
  • K2 Medical Research, 101 Southhall Lane, Suite 150
    Maitland, Florida 32751-5669, United States
  • PPD, 100 West Gore Street, Suite 202
    Orlando, Florida 32806, United States
  • Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor
    Chicago, Illinois 60611, United States
  • Mayo Clinic, 200 First Street SW
    Rochester, Minnesota 55905, United States
  • Mount Sinai Beth Israel, 10 Union Square East, Suite 5H
    New York, New York 10003, United States
  • Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street
    New York, New York 10065, United States
  • Hospital of the University of Pennsylvania, 330 S. 9th Street
    Philadelphia, Pennsylvania 19107-6103, United States
  • Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600
    Nashville, Tennessee 37212, United States
  • Shaare Zedek Medical Center, 12 Shmuel Biet Street
    Jerusalem, 91031, Israel
  • Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000
    Jerusalem, 91120, Israel
  • Sheba Medical Center, Tel Hashomer
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky Medical Center, 6 Weizmann St.
    Tel Aviv, 64239, Israel
08

References and documents

Publications

  • De BP, Rosenberg JB, Selvan N, Wilson I, Yusufzai N, Greco A, Kaminsky SM, Heier LA, Ricart Arbona RJ, Miranda IC, Monette S, Nair A, Khanna R, Crystal RG, Sondhi D. Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease. Hum Gene Ther. 2023 Sep;34(17-18):905-916. doi: 10.1089/hum.2023.067. PubMed 37624739 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Aug 2031, 139 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 139 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 15, 2019
StartActual
Jan 3, 2020
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04127578
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Jan 3, 2020
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

Travis B. Lewis, MD, PhD
study director · Prevail Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion